865 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Bought by Ingalls & Snyder LLC

Ingalls & Snyder LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, HoldingsChannel reports. The fund acquired 865 shares of the medical research company’s stock, valued at approximately $204,000.

A number of other hedge funds have also added to or reduced their stakes in CRL. VisionPoint Advisory Group LLC increased its position in Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC purchased a new position in Charles River Laboratories International during the 3rd quarter valued at $37,000. Operose Advisors LLC purchased a new position in Charles River Laboratories International during the 3rd quarter valued at $42,000. Covestor Ltd increased its position in Charles River Laboratories International by 100.0% during the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 87 shares during the period. Finally, Venturi Wealth Management LLC boosted its holdings in shares of Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock valued at $51,000 after buying an additional 112 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $241.34 on Monday. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The stock has a market capitalization of $12.43 billion, a PE ratio of 26.20, a price-to-earnings-growth ratio of 1.89 and a beta of 1.40. The firm’s 50 day moving average price is $252.64 and its 200-day moving average price is $220.31. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. During the same quarter last year, the business earned $2.98 EPS. The firm’s revenue was down 7.9% compared to the same quarter last year. Equities research analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CRL. JPMorgan Chase & Co. boosted their target price on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. Citigroup increased their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Guggenheim downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Finally, UBS Group increased their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.23.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the sale, the executive vice president now owns 13,550 shares in the company, valued at approximately $3,437,635. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now directly owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,932 shares of company stock worth $3,693,663. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).